MannKind Corporation (MNKD)

Over the past six months, MannKind's stock price has declined significantly. Positive trial results for Tyvaso DPI were reported by United Therapeutics. MannKind reported its fourth-quarter 2025 financial results, surpassing revenue forecasts but falling short on earnings per share. The FDA accepted the sBLA for Afrezza in the pediatric population for review, and the company submitted an sNDA for the FUROSCIX ReadyFlow Autoinjector. Analyst ratings have been mixed, with some downgrades and reiterated buy ratings. MannKind exchanged convertible notes for stock and cash, reducing company debt.

MannKind's common stock exhibits seasonal trading patterns, with May being the strongest month and July the weakest. Product demand has seen increased patient demand for Tyvaso DPI and Afrezza, while V-Go has experienced a decrease.

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapeutic products and devices for chronic diseases, including diabetes and orphan lung diseases. Its core business segments include diabetes management, pulmonary drug delivery, and rare and orphan diseases. Major products include Afrezza, a rapid-acting inhaled insulin; V-Go, a wearable insulin delivery device; Tyvaso DPI, for the treatment of pulmonary arterial hypertension; and FUROSCIX, a furosemide injection to treat fluid buildup. MannKind also has a pipeline of treatments for orphan lung diseases and leverages its proprietary Technosphere technology platform.

MannKind Corporation is headquartered in Danbury, Connecticut, and maintains a corporate office in Westlake Village, California. It has a manufacturing facility in Danbury, Connecticut, producing Technosphere powders and assembling inhalers. MannKind commercializes Afrezza in the United States and has partnered with Cipla to launch Afrezza in India.

MannKind's brand reputation has been influenced by its product development and financial performance. Positive developments include revenue growth, advancements in orphan lung programs, and positive clinical trial results for Tyvaso DPI. The company's focus on chronic disease care, scientific advancement, strategic partnerships, and the acquisition of scPharmaceuticals also contribute positively to its reputation.

MannKind Corporation's stock ownership includes institutional, insider, and retail investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Alfred E. Mann, the company's founder, is the largest individual shareholder.